TITAN PHARMACEUTICALS INC (TTNP) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:TTNP • US8883147055

4.61 USD
-0.18 (-3.76%)
At close: Oct 1, 2025
5.91 USD
+1.3 (+28.2%)
After Hours: 10/1/2025, 9:36:58 PM

TTNP Key Statistics, Chart & Performance

Key Statistics
Market Cap6.13M
Revenue(TTM)N/A
Net Income(TTM)-4.71M
Shares1.33M
Float670.00K
52 Week High5.76
52 Week Low3.03
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.23
PEN/A
Fwd PEN/A
Earnings (Next)01-01
IPO1996-01-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
TTNP short term performance overview.The bars show the price performance of TTNP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

TTNP long term performance overview.The bars show the price performance of TTNP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of TTNP is 4.61 USD. In the past month the price increased by 9.76%. In the past year, price decreased by -13.02%.

TITAN PHARMACEUTICALS INC / TTNP Daily stock chart

TTNP Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to TTNP. When comparing the yearly performance of all stocks, TTNP is a bad performer in the overall market: 69.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
TTNP Full Technical Analysis Report

TTNP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TTNP. While TTNP seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TTNP Full Fundamental Analysis Report

TTNP Financial Highlights

Over the last trailing twelve months TTNP reported a non-GAAP Earnings per Share(EPS) of -5.23. The EPS increased by 29.34% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -161%
ROE -192.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%66.89%
Sales Q2Q%N/A
EPS 1Y (TTM)29.34%
Revenue 1Y (TTM)-100%
TTNP financials

TTNP Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
TTNP Analyst EstimatesTTNP Analyst Ratings

TTNP Ownership

Ownership
Inst Owners3.56%
Ins Owners29.69%
Short Float %N/A
Short RatioN/A
TTNP Ownership

TTNP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.54969.015B
JNJ JOHNSON & JOHNSON20.46574.257B
MRK MERCK & CO. INC.21.65290.769B
PFE PFIZER INC9.19156.982B
BMY BRISTOL-MYERS SQUIBB CO10123.896B
ZTS ZOETIS INC18.6656.466B
RPRX ROYALTY PHARMA PLC- CL A8.5225.52B
VTRS VIATRIS INC6.3118.371B
ELAN ELANCO ANIMAL HEALTH INC24.512.725B
AXSM AXSOME THERAPEUTICS INC225.049.291B

About TTNP

Company Profile

TTNP logo image Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Company Info

TITAN PHARMACEUTICALS INC

Suite 505, 400 Oyster Point Blvd

San Francisco CALIFORNIA 94080 US

CEO: Marc Rubin

Employees: 4

TTNP Company Website

TTNP Investor Relations

Phone: 14152444990

TITAN PHARMACEUTICALS INC / TTNP FAQ

What does TTNP do?

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. The company is headquartered in San Francisco, California. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.


Can you provide the latest stock price for TITAN PHARMACEUTICALS INC?

The current stock price of TTNP is 4.61 USD. The price decreased by -3.76% in the last trading session.


What is the dividend status of TITAN PHARMACEUTICALS INC?

TTNP does not pay a dividend.


What is the ChartMill rating of TITAN PHARMACEUTICALS INC stock?

TTNP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of TTNP stock?

TITAN PHARMACEUTICALS INC (TTNP) operates in the Health Care sector and the Pharmaceuticals industry.


Would investing in TITAN PHARMACEUTICALS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TTNP.


Can you provide the upcoming earnings date for TITAN PHARMACEUTICALS INC?

TITAN PHARMACEUTICALS INC (TTNP) will report earnings on 2026-01-01.